INVO Fertility posted fiscal 2025 revenue of $6.8 million, a 5% increase year-over-year, while net losses from continuing operations improved to $5.3 million from $7.7 million. The company strengthened its balance sheet through $11.5 million in financing, acquired a fourth fertility clinic in Indiana, and secured a new patent for its INVOcell device, positioning for growth in the specialized fertility services market.